Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2025-12-01 00:00:00 ET · period of report 2025-09-05 · accession 0001193125-25-304212 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-01 | 2025-12-01 | MGX | Irish Jian | CEO, Dir | A - Grant | $1.60 | +248.5K | 565.4K | +78% | +$397.6K |
| D | 2025-12-01 | 2025-09-05 | MGX | Irish Jian | CEO, Dir | S - Sale | $1.81 | -1,602 | 316.9K | -0.5% | -$2,900 |
| D | 2025-12-01 | 2025-12-01 | MGX | Irish Jian | CEO, Dir | A - Grant | $0.00 | +225.0K | 225.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-01 | A | A | 37,500 | $1.60 | 354,441 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-05 | S | D | 1,602 | $1.81 | 316,941 | D | — | — | (F2) Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 30, 2025 and 1,500 shares acquired under the Company's ESPP on November 28, 2025. |
| 3 | Common | Common Stock | 2025-12-01 | A | A | 211,000 | $1.60 | 565,441 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-12-01 | A | A | 225,000 | $0.00 | 225,000 | D | $1.60 · — to 2035-11-30 | 225,000 Common Stock | (F5) 25% of the shares subject to this option shall vest and become exercisable on November 6, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |